At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 254 enrolled
Drug / intervention
Apremilast +2 moredrug
Likely dose
Apremilast 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis
In Brief
A Phase 2 clinical trial evaluating Apremilast and Placebo for Psoriasis and 2 related conditions. Completed, enrolled 254 participants across 56 sites.
Detailed Summary
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedNov 2013
Primary CompletionNov 2014
Study CompletionDec 2015
TodayJul 2026
First PostedNov 20, 2013
Enrollment StartJul 9, 2013
Primary CompletionNov 20, 2014
Study CompletionDec 15, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.6 years ago
Interventions
Apremilastdrug
20 mg tablet BID for 68 weeks
Apremilastdrug
20 mg tablet BID for 68 weeks
Placebodrug
Placebo tablet BID for 16 weeks